Ongoing Projects

Title:
ICMR CAR Phase I Clinical Trials
Sponsor:
ICMR
Principal Investigator:
Dr. Melvin George
Co-Investigator:
Dr. Sangeetha Raja, Dr. Kumaravel J, Dr. Preethika A
Duration:
2023 - 2028
Sanctioned Amount:
I year - 1.3 crores
II year - 64 lacs
III year - 67 lacs
Title:
A seamless, randomized, double-blind, placebo-controlled single-centre Phase I study in healthy Indian adult participants followed by an active comparator controlled, multi-centric Phase II open label study in healthy adult participants and an elderly population to evaluate the safety, reactogenicity, and immunogenicity of Mynflu001, a recombinant, adjuvanted Influenza Vaccine
Sponsor:
ICMR
Principal Investigator:
Dr. Melvin George
Co-Investigator:
Dr. J S Kumar, Dr. C M Dhileeban, Dr. Kumaravel J
Duration:
2024 - 2027
Sanctioned Amount:
4.78 crores
Title:
A First-in-human, Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Recombinant Live attenuated Zika Vaccine (Freeze Dried) of Human Biologicals Institute, in Healthy Adult Volunteers aged 18 to 50 years.
Sponsor:
ICMR
Principal Investigator:
Dr. Sangeetha Raja
Co-Investigator:
Dr. Kumaravel J, Dr. Preethika A, Dr Anusha G, Dr P. Kaveri
Duration:
2026 - 2028
Sanctioned Amount:
69 lacs
Title:
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophilized) – “DengiAll” of Panacea Biotec Limited in Healthy Indian Adults.
Sponsor:
ICMR & PANACEA
Principal Investigator:
Dr. Melvin George
Co-Investigator:
Dr. Logaraj M, Dr. K.V. Leela, Dr. K. Subramaniyan, Dr. M.V.M. Pradeep, Dr. Kumaravel, Dr. Aamina Hussain
Duration:
2+ Years
Sanctioned Amount:
76 lacs
Title:
A Phase II/III, Multicentre, Observer-Blind, Randomized, Active- controlled Study to Evaluate Immunogenicity and safety of A Trivalent Nanoparticle Influenza Vaccine and Covid- Influenza Combination Vaccine Compared with Licensed Influenza and Covid-19 Vaccines in Adults
Sponsor:
Serum Institute Pvt Ltd
Principal Investigator:
Dr. Melvin George
Co-Investigator:
Dr. Aneesh Basheer, Dr. Kumaravel, Dr. Subramaniyam
Duration:
6 Months
Sanctioned Amount:
-
Title:
A phase 2/3, double-blind, randomized, active-controlled, multicentric study to evaluate the safety, immunogenicity and lot-to-lot consistency of a bivalent conjugate vaccine against Salmonella enterica serovars Typhi and Paratyphi A in healthy individuals aged 6 months to 65 years (Protocol No.: TCV-02)
Sponsor:
Serum Institute Pvt Ltd
Principal Investigator:
Dr. Vijay Anand
Co-Investigator:
Dr. Melvin George, Dr. Jerin James
Duration:
6 Months
Sanctioned Amount:
-
Title:
A Phase 3 study in India to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus (RSV) Vaccine in Adults
Sponsor:
Pfizer
Principal Investigator:
Dr. Sangeetha Raja
Co-Investigator:
Dr. Kumaravel, Dr. Meenakshi Sundari, Dr. Kaveri, Dr. Subramaiyam
Duration:
1 Year
Sanctioned Amount:
-
Title:
A Phase IV Multicentric, Post-marketing Study Evaluating the Safety, Immunogenicity and Efficacy of the Marketed Formulation of Hetero Trastuzumab in Female Patients with HER2+ Breast Cancer
Sponsor:
Hetero Biopharma Limited
Principal Investigator:
Dr. Karthikeyan
Co-Investigator:
Dr. Manisha, Dr. Senthil
Duration:
1 Year
Sanctioned Amount:
-
Title:
A Real-world Prospective Study to Evaluate the Geographical Distribution of Prevalence, Sensitization rate, and Utilization of Prophylactic Treatment of RH-negative Women in India
Sponsor:
BSV
Principal Investigator:
Dr. Sajeetha Kumari
Co-Investigator:
Dr. Vidhyalakshmi
Duration:
3 Years
Sanctioned Amount:
-
Title:
Collection of Blood and Sputum Samples from Healthy Subjects and Patients with Lung Cancer for Characterization of Cancer Biomarkers to Develop an Early-stage Liquid Biopsy-based Cancer Screening test
Sponsor:
Oxford Cancer Analytics
Principal Investigator:
Dr. J.S. Kumar
Co-Investigator:
Dr. Amina Hussain
Duration:
3+ Years
Sanctioned Amount:
-
Title:
A Phase IV, Post-marketing, Prospective, Multicenteric, Single Arm, Non-comparative Study to Evaluate the Safety and Efficacy of Polmacoxib 2mg in Adult Patients with Osteoarthritis of Hip/Knee.
Sponsor:
Hetero Biopharma Limited
Principal Investigator:
Dr. Vijay Anand.B
Co-Investigator:
Dr. Rishab
Duration:
2 Years
Sanctioned Amount:
-
Title:
A Phase IV Post-marketing Prospective, Multicentre, Single-arm Clinical Study to Evaluate the Safety, Efficacy and Inmunogenecity of Hetero Tenectiplase for Thrombolysis in Acute Myocardial Infarction
Sponsor:
Hetero Biopharma Limited
Principal Investigator:
Dr. Ranjith
Co-Investigator:
-
Duration:
2 Years
Sanctioned Amount:
-

Completed Projects

Title:
A Single-arm, Open-label, Multi-center, Phase IV Trial to evaluate the Reactogenicity safety and immunogenicity of a Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants aged 65 years and Older in India.
Sponsor:
Glaxo smith Klein
Principal Investigator:
Dr. Satyajit Mohapatra
Co-Investigator:
Dr.P.Kaveri
Duration:
2024
Sanctioned Amount:
-
Title:
Improved Data on Dengue Covering Differences in Epidemiological Surveillance, Patient Demographics, The Health Seeking Behavior of Patients and Standards of Care
Sponsor:
DNDi
Principal Investigator:
Dr. Satyajit Mohapatra
Co-Investigator:
Dr. Roshini Mary Peter
Duration:
2024
Sanctioned Amount:
-
Title:
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once weekly versus Tirzepatide 15 mg s.c. Once weekly in Participants with Type 2 Diabetes Inadequately Controlled on Metformin with or without an SGLT2 Inhibitor Protocol ID – NN9388-4894
Sponsor:
Novo Nordisk
Principal Investigator:
Dr. J.S. Kumar
Co-Investigator:
Dr. Venkatesan, Dr. Abinaya
Duration:
2024-2026
Sanctioned Amount:
-
Title:
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in healthy adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa.(MEQ00064)
Sponsor:
Shantha Biotechnics Pvt. Ltd, (A Sanofi Company)
Principal Investigator:
Dr. Sangeetha Raja
Co-Investigator:
Dr.S.Vijayanand
Duration:
2023-2026
Sanctioned Amount:
-
Title:
A randomized, double-blind, multi-center, active-control, parallel group study to compare efficacy, safety, immunogenicity and pharmacokinetics of Lupin’s Nivolumab (LUBT022) with Innovator’s Nivolumab in patients with locally advanced or metastatic non- small cell lung cancer
Sponsor:
LUPIN
Principal Investigator:
Dr.S.Karthikeyan
Co-Investigator:
Dr.MS Manisha, Dr.Kumaravel J, Dr.Prasitha K
Duration:
2025-2026
Sanctioned Amount:
-
Title:
A Randomized, Double-blind, Placebo-controlled, Phase 3 trial to investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Subcutaneously to Healthy Subjects aged 4 to 60 years in India. (Den-302)
Sponsor:
TAKEDA
Principal Investigator:
Dr. Jerin James
Co-Investigator:
-
Duration:
2024-2025
Sanctioned Amount:
-
Title:
To Assess the Safety of SIIPL’s qHPV Vaccine when Administered in a two-dose Schedule to Girls and Boys aged 9-14 years and in a Three-dose Schedule to Women and aged 15-26 years.
Sponsor:
Serum Institute of India
Principal Investigator:
Dr.R.Sajeetha Kumari
Co-Investigator:
Dr.M.Anuradha
Duration:
2024-2025
Sanctioned Amount:
-
Title:
A Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study of DRL_AB, US licensed Reference Abatacept (Orencia®) and EU approved Reference (Orencia®), Administered by the Subcutaneous Route to Male Normal Healthy Volunteers.
Sponsor:
DR REDDY's
Principal Investigator:
Dr. Sangeetha Raja
Co-Investigator:
-
Duration:
2025
Sanctioned Amount:
-
Title:
An open label, multicentre, randomized, single-dose, parallel, two-treatment, bioequivalence study of Ferric Carboxymaltose Injection 750 mg/15mL (50 mg/mL) of RK Pharma Inc. with INJECTAFER® (Ferric Carboxymaltose Injection 750 mg/15 mL [50mg/mL]) of American Regent, Inc. Shirley, NY 11967, following a single intravenous dose of 750mg in adult human patients with iron deficiency anaemia.
Sponsor:
RK PHARMA
Principal Investigator:
Dr. Sajeetha Kumari
Co-Investigator:
Dr. Aneesh Basher, Dr.SN Meenakshi Sundari, Dr. Melvin George
Duration:
2025-2026
Sanctioned Amount:
-
Title:
To Assess the Efficacy, Safety, and Immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for Prevention Against COVID-19 in adults 18 years of age and Older/ VAT00008.(Stage-2)
Sponsor:
Sanofi
Principal Investigator:
Dr. Satyajit Mohapatra
Co-Investigator:
Dr. Sangeetha Raja
Duration:
2021-2024
Sanctioned Amount:
-